======= ARTW ========
-Low floater
-Trading almost 100% below its book value of $4.29
-Revolving line of credit with zero dilution
-57% insider ownership
-Bullish outlook into 2025 with Donald Trump's new goals for agriculture
-Well below its market cap of its direct competitors
$NTBL $IMG $PRDS
$KNTE "In our capacity as a stockholder of the Company, we would not vote in favor of any alternative sale, merger or similar transaction involving the Company." I've seen this exact situation previously with $PRDS. This company will be bought out very soon.
#TAKEAWAY
$PRDS $53.88 +1.23. DAC $54.54 - last $52.70 (9.28.23) EXIT $59.25.
RETAIN POSITION.
Annual recurring revenue is the key demand metric for PRGS and, in the words of CFO Anthony Folger, provides the best view of its underlying performance. In Q3, ARR increased by 18% on a constant currency basis to $577 mln. The growth essentially matches last quarter's increase of 19% and was supported by a solid retention rate that was just under 101%.
On the topic of MarkLogic, PRGS stated that its performing in line with expectations and that the integration of the business is on track to meet the anticipated timeline. The $355 mln deal, which was completed in February 2023, bolstered PRGS's infrastructure software portfolio by adding NoSQL database and semantic metadata management products.
note: MarkLogic should add more than $100 mln in annual revenue, contribute strong cash flows, and be accretive to earnings in FY24.
$COCP Finally the true GAME-CHANGER CDI-988 molecule after 3.5 preclinical (Cocrystal is the gold standard in preclinical) which differentiates in ALL the other pre clinical small molecule biotechs who have ALL rushed and failed their COVID drug clinical trials $ENTA $PRDS $AVIR etc. Reminder Fred Hassan who purchased 1M shares, KEY board member and the PHARMA LEGEND and what ever he touches turns to gold. Last one back in April was the Merck M&A $11B $RXDX. Things are going to heat up!!
$PRDS cash is now available in my account as of this morning.
Looking forward to that CVR!
The patent is vastly encompassing. I'd be flabbergasted if they don't cash in on it one way or another.
$PRDS MediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes Biosciences
https://www.stocktitan.net/news/PRDS/medi-pacific-offering-2-13-per-share-plus-one-contingent-value-right-1ceehzjunses.html
#offering
